ArticleHuman vaccines & immunotherapeutics2026
Herpes zoster vaccination among older adults in urban China: A mixed-methods study in Shenzhen.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster (HZ) poses a growing burden in aging populations, yet uptake of herpes zoster vaccines (HZVs) remains limited in China. This mixed-methods study examined HZV willingness and barriers among older adults in Shenzhen. We conducted a cross-sectional survey among older adults (N = 1,974), and semi-structured interviews with older adults and healthcare providers (HCPs) (N = 30). Quantitative analyses used a multinomial outcome (unwilling, hesitant, willing), while qualitative data were thematically analyzed and integrated with survey results using a joint display. Findings revealed that only 8.4% of respondents had received HZV, while 33.7% of unvaccinated participants (N = 1,809) expressed future HZV willingness. In multinomial regression, willingness (vs unwillingness) was associated with awareness of local HZV policy (aOR = 1.82, 95% CI: 1.38-2.40), awareness of HZV (aOR = 1.77, 95% CI: 1.34-2.35), previous SIV vaccination (aOR = 1.72, 95% CI: 1.32-2.22), awareness of life-course immunization (aOR = 1.69, 95% CI: 1.22-2.33), and female gender (aOR = 1.34, 95% CI: 1.06-1.70). Hesitancy (vs unwillingness) was associated with prior influenza vaccination (aOR = 1.76, 95% CI: 1.35-2.29) and prior COVID-19 infection (aOR = 1.46, 95% CI: 1.02-2.08), while age over 70 was associated with lower odds of hesitancy (aOR = 0.72, 95% CI: 0.53-0.98). Cost, unfamiliarity with HZV and low perceived risk were commonly reported barriers. Interviews described anticipated pain and trusted recommendations from HCPs and family as salient cues, alongside barriers related to affordability, limited awareness, concerns about side effects, reliance on traditional remedies, and constrained institutional support. Overall, HZV uptake among older adults in urban China remains suboptimal. Strategies to improve awareness, reduce financial barriers, and engage HCPs are critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.